ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Jun 03, 2022 16:37 JST
Source:
Eisai
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting
TOKYO, Jun 03, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States.
Major poster presentations include the results of a subgroup analysis of the Phase III 304 clinical study on the effect of lemborexant treatment in older adults with insomnia and objectives of short sleep which is characterized by sleeping fewer than six hours (Posters #171 and #172).
"DAYVIGO continues to serve as an important asset to Eisai's neurology portfolio and we look forward to presenting the findings from several analyses at this year's SLEEP Meeting," said Ivan Cheung, Eisai Inc., Senior Vice President, President Neurology Business Group, Eisai Co., Ltd. "Insomnia can lead to daytime consequences; fatigue, difficulty concentrating and irritability,(1),(2) and causes distress or impairs functioning in social and occupational settings. Eisai remains committed to our pursuit of helping people suffering from insomnia to help address unmet medical needs."
(1) Ferrie JE, et al. Sleep epidemiology - a rapidly growing field. Int J Epidemiol. 2011;40(6):1431-1437.
(2) Roth T. Insomnia: definition, prevalence, etiology and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7-S10
About Lemborexant (product name: DAYVIGO)
Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in over 10 countries including Japan, the United States and countries in Asia.
For more information, visit www.eisai.com/news/2022/news202244.html.
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Value Research Center (VRC) at SSUNGA78: 'How Purpose, Value, and Impact will Drive a Sustainable Post- SDG Future'
Sep 22, 2023 21:00 JST
TOYOTA GAZOO Racing returns to South American roads
Sep 22, 2023 18:26 JST
Fujitsu marks next stage of "Work Life Shift" with new corporate hubs in Tokyo area to boost productivity, data-driven management
Sep 22, 2023 16:20 JST
Fujitsu and Hokuhoku Financial Group launch trials for generative AI to streamline operations for Hokuriku Bank and Hokkaido Bank
Sep 22, 2023 12:32 JST
Innovative MedTech Welcomes Visionary Frederick Schilling to its Corporate Advisory Board
Sep 21, 2023 22:30 JST
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21
Sep 21, 2023 12:26 JST
JCB and BNI Launch the BNI JCB Ultimate Card
Sep 21, 2023 09:00 JST
Takasago Hydrogen Park, the World's First Integrated Validation Facility for Technologies from Hydrogen Production to Power Generation, Enters Full-Scale Operation
Sep 20, 2023 19:05 JST
HRC and Takaaki Nakagami Agree to Renew Contract
Sep 20, 2023 15:24 JST
Lexus Presents the Theme of Diversification and Electrification Aiming to Deliver New Value to Customers
Sep 20, 2023 11:22 JST
Hitachi Industrial Products to Launch High-capacity Multi-port EV Charger
Sep 19, 2023 20:06 JST
Honda and Toray Begin Joint Demonstration of Closed-loop Recycling of Nylon Resin
Sep 19, 2023 12:07 JST
Fujitsu launches new offering to support sustainable enterprise transformation as Japan's first premium supplier for RISE with SAP
Sep 19, 2023 10:34 JST
Fujitsu strengthens DX consulting capabilities with plans to acquire Australian consultancy MF & Associates - investing for government and healthcare customer success
Sep 19, 2023 10:05 JST
Quantum Computing Startup - Nanofiber Quantum Technologies Secures $8.5m Funding
Sep 18, 2023 04:40 JST
SBM Offshore and MHI Sign Partnership Agreement for FPSO CO2 Capture Solution
Sep 15, 2023 18:51 JST
Fujitsu and the Linux Foundation launch Fujitsu's automated machine learning and AI fairness technologies as Linux Foundation hosted open source projects
Sep 15, 2023 10:23 JST
A New Era: Challenges in Lunar Exploration and Manned Lunar Orbital Base Development
Sep 14, 2023 17:04 JST
MHI Becomes a Full Member of the Japan Center for Engagement and Remedy on Business and Human Rights (JaCER)
Sep 14, 2023 14:45 JST
Fujitsu and Baptist Health South Florida transform operating room scheduling with newly launched solution to boost utilization rates and the financial health of the surgical discipline
Sep 14, 2023 10:33 JST
More Latest Release >>
Related Release
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21
9/21/2023 12:26:00 PM JST
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem
9/12/2023 7:05:00 PM JST
Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment
8/4/2023 1:04:00 PM JST
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
7/20/2023 11:23:00 AM JST
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research
7/12/2023 10:05:00 AM JST
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
7/7/2023 1:21:00 PM JST
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced
6/30/2023 11:08:00 AM JST
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City
6/22/2023 5:08:00 PM JST
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
6/12/2023 10:13:00 AM JST
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
6/8/2023 1:32:00 PM JST
More Press release >>